Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Circle Pharma, Inc.

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma to Participate in Upcoming Investor Conferences
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
From Circle Pharma, Inc.
Via Business Wire
Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Appoints Evelyn Wang, PhD as its Vice President, Translational Medicine
From Circle Pharma, Inc.
Via Business Wire
Circle Pharma Raises $66 Million in Series C Financing
From Circle Pharma, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.